Nathalie Adda
Overview
Explore the profile of Nathalie Adda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feld J, Lawitz E, Nguyen T, Lalezari J, Hassanein T, Martin P, et al.
Antivir Ther
. 2022 Nov;
27(6):13596535221127848.
PMID: 36382358
Background: Chronic hepatitis B (CHB) remains a major cause of morbidity and mortality. EDP-514 is a potent core inhibitor of hepatitis B virus (HBV) that reduces viral load reduction in...
2.
Marotta C, Ahmad A, Luo E, Oosterhaven J, van Marle S, Adda N
Clin Transl Sci
. 2022 Nov;
16(2):338-351.
PMID: 36369848
EDP-297 is a farnesoid X receptor agonist under development for treating nonalcoholic steatohepatitis. The pharmacokinetic (PK), pharmacodynamic (PD), food effect, and safety were evaluated in a single ascending dose (SAD)...
3.
Ahmad A, Adda N
Clin Transl Sci
. 2022 Jun;
15(9):2146-2158.
PMID: 35675500
EDP-305 is a farnesoid X receptor (FXR) agonist that selectively activates FXR and is a potential treatment for patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. Results from preclinical studies...
4.
Ahmad A, Eze K, Noulin N, Horvathova V, Murray B, Baillet M, et al.
N Engl J Med
. 2022 Feb;
386(7):655-666.
PMID: 35172056
Background: Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral...
5.
Ratziu V, Rinella M, Neuschwander-Tetri B, Lawitz E, Denham D, Kayali Z, et al.
J Hepatol
. 2021 Nov;
76(3):506-517.
PMID: 34740705
Background & Aims: EDP-305 is an oral farnesoid X receptor (FXR) agonist under development for the treatment of non-alcoholic steatohepatitis (NASH). Herein, we aimed to assess the efficacy, safety and...
6.
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin C, et al.
Hum Vaccin Immunother
. 2019 Aug;
16(2):388-399.
PMID: 31373537
Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050...
7.
Flamm S, Muir A, Fried M, Reddy K, Nelson D, Bzowej N, et al.
J Clin Gastroenterol
. 2014 May;
49(4):336-44.
PMID: 24828357
Background: The phase 3 studies of telaprevir (T) in combination with peginterferon α-2a and ribavirin (PR) in treatment-naive genotype 1 chronic hepatitis C virus-infected patients (ADVANCE/ILLUMINATE) were not designed a...
8.
Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer T, et al.
J Clin Virol
. 2014 Jan;
59(3):148-55.
PMID: 24462470
Background: Telaprevir-based therapy is associated with rapid decline in HCV RNA, enabling the application of early futility rules. Objectives: To familiarize physicians with this paradigm, a comprehensive analysis of the...
9.
Sulkowski M, Sherman K, Dieterich D, Bsharat M, Mahnke L, Rockstroh J, et al.
Ann Intern Med
. 2013 May;
159(2):86-96.
PMID: 23685940
Background: Telaprevir (TVR) plus peginterferon-α2a (PEG-IFN-α2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic hepatitis C virus (HCV) infection versus PEG-IFN-α2a-ribavirin alone. Its safety and efficacy in patients...
10.
Sullivan J, De Meyer S, Bartels D, Dierynck I, Zhang E, Spanks J, et al.
Clin Infect Dis
. 2013 Apr;
57(2):221-9.
PMID: 23575197
Background: Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples...